Associations between glucolipid metabolic indices with the risk and progression of cardiovascular-kidney-metabolic syndrome in MASLD: evidence from the UK biobank
Metabolic dysfunction–associated steatotic liver disease (MASLD) affects nearly one-third of the global population and increases the risk of adverse hepatic and extrahepatic outcomes. However, its contribution to multimorbidity trajectories remains insufficiently defined. The current Cardiovascular -Kidney-Metabo...